Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Osteoarthritis,Knee
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 45 Years to 79 Years
Enrollment: 4,185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2020
U.S. locations: 3
States / cities: Birmingham, Alabama • Iowa City, Iowa • Boston, Massachusetts

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation
Interventions: Informational Intervention, Survey Administration; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Volunteers
Interventions: Drug: ABBV-1088, Drug: Placebo for ABBV-1088; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy Volunteers
Interventions: [^14C]-LY2835219; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Nicotine Addiction
Interventions: transcranial direct current stimulation (tDCS); Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 61 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more

Conditions: Non-Hodgkin Lymphoma
Interventions: Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Duarte, California • Chesterfield, Missouri • Austin, Texas + 1 more

Conditions: Healthy Volunteers
Interventions: TAK-385 T2 Formulation, TAK-385 T4 Formulation B, TAK-385 T4 Formulation C; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Mucopolysaccharidosis IIIB
Interventions: SBC-103; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Pittsburgh, Pennsylvania

Conditions: Nicotine Dependence
Interventions: Placebo, Varenicline; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Generalized Myasthenia Gravis, gMG
Interventions: Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone; Procedure · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Chicago, Illinois • Schaumburg, Illinois • Neptune City, New Jersey + 2 more

Conditions: Prostate Cancer
Interventions: Patient Education; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Interventions: Stereotactic body radiotherapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Sleep, Executive Functioning, Sleep Hygiene, Health Literacy
Interventions: Psychoeducational Sleep Intervention; Behavioral
Lead sponsor: Northern Arizona University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Aphasia, Stroke, Stroke, Ischemic, Aphasia, Broca, Aphasia, Global, Aphasia, Mixed, Aphasia, Jargon, Aphasia, Expressive, Aphasia, Conduction, Aphasia, Fluent, Aphasia, Anomic
Interventions: Semantically focused treatment, Phonologically focused treatment; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 21 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Charleston, South Carolina • Columbia, South Carolina

Conditions: Parkinson Disease
Interventions: Occupational therapy intervention group, Disease management education group; Behavioral
Lead sponsor: San Jose State University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: San Jose, California • New York, New York

Conditions: Long QT Syndrome Type 3
Interventions: Eleclazine, Eleclazine placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Rochester, Minnesota • New York, New York • Rochester, New York

Conditions: Smoking Cessation, Obesity
Interventions: Self-Regulation strategies + large changes (SR), Healthy Lifestyle Education (LE), Smoking Cessation Treatment; Behavioral · Other
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Acute Lymphoblastic Leukemia
Interventions: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Phenylketonuria (PKU)
Interventions: JNT-517; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Gainesville, Florida • Tampa, Florida • Portland, Oregon + 4 more

Conditions: Nicotine Dependence, Opiate Dependence
Interventions: Intensive, tailored intervention, NJ Quitline Referral; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BG00002 (natalizumab); Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 53
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more

Conditions: Depression, Major Depressive Disorder
Interventions: Transcranial Light Therapy, Sham Transcranial Light Therapy; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts • Orangeburg, New York

Conditions: DCIS, Breast Cancer, Breast Neoplasms, Sentinel Lymph Node
Interventions: Delayed SLND, Late SLND; Diagnostic Test
Lead sponsor: Uppsala University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Multicenter Bone and Joint Health Study

Usefulness of Video-Based Intervention in Helping Participants Encourage Their Families to Get Tested for BRCA Gene Mutations

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants

tDCS Effects on Resisting Smoking: Dose Ranging Study

A Study of Cariprazine in Patients With Chronic Stable Schizophrenia

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants

Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)

Effects of Chantix on Relapse Prevention for Smoking Cessation

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Online Sleep Education for College Student's Sleep Health and Executive Functioning

Modeling Treated Recovery From Aphasia

Pre-Active PD: Looking At Physical Activity Behavior Change in Parkinson's Disease

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

A Multiple Health Behavior Change Intervention for Overweight and Obese Smokers

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

A Long-Term Study of JNT-517 in Participants With Phenylketonuria

Developing a Smoking Cessation Intervention for Methadone Maintained Smokers

Natalizumab Re-Initiation of Dosing

Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3)

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ